Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

Breast Cancer Research and Treatment

Volumn 128, Issue 2, 2011, Pages 347-356

  Junttila, Teemu T ^a   Li, Guangmin ^a   Parsons, Kathryn ^a   Phillips, Gail Lewis ^a   Sliwkowski, Mark X ^a  

^a GENENTECH INC   (United States)

Author keywords

Antibody drug conjugate (ADC); Breast cancer; ErbB2; HER2; Therapeutic antibodies; Trastuzumab; Trastuzumab DM1 (T DM1)

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; LAPATINIB; MAYTANSINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CHEMOSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; MAYTANSINE; MICE; MICE, NUDE; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 79959700509     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1090-x     Document Type: Article

References (34)

1. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10963602 10.1038/35021093 1:CAS:528: DC%2BD3cXmt1CnsLw%3D
2. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D (Pubitemid 17231334)
3. DJ Slamon W Godolphin LA Jones, et al. 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 2470152 10.1126/science.2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D (Pubitemid 19147683)
4. P Carter L Presta CM Gorman, et al. 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285 4289 1350088 10.1073/pnas.89.10.4285 1:CAS:528:DyaK3sXitFSqtb0%3D
5. HS Cho K Mason KX Ramyar, et al. 2003 Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 421 756 760 12610629 10.1038/nature01392 1:CAS:528:DC%2BD3sXhsV2rtrw%3D (Pubitemid 36227628)
6. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
7. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
8. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 11248153 10.1056/NEJM200103153441101 1:CAS:528:DC%2BD3MXisVGktrc%3D (Pubitemid 32222155)
9. H Joensuu PL Kellokumpu-Lehtinen P Bono, et al. 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820 16495393 10.1056/NEJMoa053028 1:CAS:528:DC%2BD28Xhsl2gsrY%3D (Pubitemid 43290919)
10. ® (Trastuzumab) Semin Oncol 26 Suppl 12 60 70 10482195 1:CAS:528:DyaK1MXmt1SisbY%3D (Pubitemid 29411434)
11. TT Junttila RW Akita K Parsons, et al. 2009 Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 Cancer Cell 15 429 440 19411071 10.1016/j.ccr.2009.03.020 1:CAS:528:DC%2BD1MXmvVGitrg%3D
12. GD Lewis I Figari B Fendly, et al. 1993 Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies Cancer Immunol Immunother 37 255 263 8102322 10.1007/BF01518520 1:CAS:528:DyaK2cXhtlWrtrk%3D (Pubitemid 23300507)
13. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 443 446 10742152 10.1038/74704 1:CAS:528:DC%2BD3cXisVOru7Y%3D (Pubitemid 30208162)
14. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743 17192538 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D (Pubitemid 46021510)
15. GD Lewis Phillips G Li DL Dugger, et al. 2008 Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res 68 9280 9290 19010901 10.1158/0008-5472.CAN-08-1776 1:CAS:528: DC%2BD1cXhtlOmt7rK
16. RV Chari BA Martell JL Gross, et al. 1992 Immunoconjugates containing novel maytansinoids: promising anticancer drugs Cancer Res 52 127 131 1727373 1:CAS:528:DyaK38Xht1Snu7s%3D
17. S Remillard LI Rebhun GA Howie SM Kupchan 1975 Antimitotic activity of the potent tumor inhibitor maytansine Science 189 1002 1005 1241159 10.1126/science.1241159 1:CAS:528:DyaE2MXlvVyht7k%3D
18. BF Issell ST Crooke 1978 Maytansine Cancer Treat Rev 5 199 207 367597 10.1016/S0305-7372(78)80014-0 1:STN:280:DyaE1M7gsFektw%3D%3D (Pubitemid 9109517)
19. CD Austin X Wen L Gazzard C Nelson RH Scheller SJ Scales 2005 Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates Proc Natl Acad Sci USA 102 17987 17992 16322102 10.1073/pnas.0509035102 1:CAS:528:DC%2BD2MXhtlersrzM (Pubitemid 41798489)
20. IE Krop M Beeram S Modi, et al. 2010 Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer J Clin Oncol 28 2698 2704 20421541 10.1200/JCO.2009.26.2071 1:CAS:528:DC%2BC3cXoslykt7c%3D
21. J Kurebayashi T Otsuki CK Tang, et al. 1999 Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6 Br J Cancer 79 707 717 10070858 10.1038/sj.bjc.6690114 1:CAS:528:DyaK1MXhslCns7k%3D (Pubitemid 29082094)
22. PJ Munson D Rodbard 1980 Ligand: a versatile computerized approach for characterization of ligand-binding systems Anal Biochem 107 220 239 6254391 10.1016/0003-2697(80)90515-1 1:CAS:528:DyaL3cXlvVagtbs%3D
23. EE Idusogie LG Presta H Gazzano-Santoro, et al. 2000 Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc J Immunol 164 4178 4184 10754313 1:CAS:528:DC%2BD3cXis1WksrY%3D (Pubitemid 30215076)
24. PE Sias CE Kotts D Vetterlein M Shepard WL Wong 1990 ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids J Immunol Methods 132 73 80 1975263 10.1016/0022-1759(90)90400-P 1:CAS:528:DyaK3cXls1ynsL0%3D (Pubitemid 20263864)
25. D Finkle ZR Quan V Asghari, et al. 2004 HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice Clin Cancer Res 10 2499 2511 15073130 10.1158/1078-0432.CCR-03-0448 1:CAS:528:DC%2BD2cXivFSqsbw%3D (Pubitemid 38445712)
26. HK Erickson PU Park WC Widdison, et al. 2006 Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing Cancer Res 66 4426 4433 16618769 10.1158/0008-5472.CAN-05-4489 1:CAS:528:DC%2BD28XjsFSlurs%3D
27. A Musolino N Naldi B Bortesi, et al. 2008 Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer J Clin Oncol 26 1789 1796 18347005 10.1200/JCO.2007.14.8957 1:CAS:528:DC%2BD1cXmsFemsLg%3D
28. RL Shields AK Namenuk K Hong, et al. 2001 High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R J Biol Chem 276 6591 6604 11096108 10.1074/jbc.M009483200 1:CAS:528: DC%2BD3MXhslShurs%3D
29. FM Yakes W Chinratanalab CA Ritter W King S Seelig CL Arteaga 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res 62 4132 4141 12124352 1:CAS:528:DC%2BD38XlsV2ltr0%3D (Pubitemid 34791085)
30. MA Molina J Codony-Servat J Albanell F Rojo J Arribas J Baselga 2001 Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells Cancer Res 61 4744 4749 11406546 1:CAS:528:DC%2BD3MXks1Grtbo%3D (Pubitemid 32691885)
31. PJ Eichhorn M Gili M Scaltriti, et al. 2008 Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 Cancer Res 68 9221 9230 19010894 10.1158/0008-5472.CAN-08-1740 1:CAS:528:DC%2BD1cXhtlOmt73F
32. Y Nagata KH Lan X Zhou, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 15324695 10.1016/j.ccr.2004.06.022 1:CAS:528:DC%2BD2cXns1arsr8%3D (Pubitemid 39485684)
33. D Hanahan RA Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10647931 10.1016/S0092-8674(00)81683-9 1:CAS:528:DC%2BD3cXks1CktA%3D%3D (Pubitemid 30046295)
34. I Smith M Procter RD Gelber, et al. 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36 17208639 10.1016/S0140-6736(07)60028-2 1:CAS:528:DC%2BD2sXit12itg%3D%3D (Pubitemid 46039831)